drugset / Trial / NCT00421343

Secondary Prevention of Osteoporosis

NCT00421343

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to develop and implement an evidence based protocol for the secondary prevention of osteoporotic fractures and falls, and to determine how compliance with this intervention improves muscle strength and functional status following a fracture.

Timeline

Start
2007-02
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 70 mg Oral
Subject Calcium carbonate Other / unclassified 500 mg Oral
Subject Cholecalciferol Other / unclassified 200 iu Oral
Subject Cholecalciferol Other / unclassified 2800 iu Oral

Indications